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Objective: To evaluate prospectively the response of left ventricular ejection fraction (LVEF) to high dose
dobutamine infusion in patients showing substantial viability, with and without improved resting LVEF after
revascularisation.
Methods: Before and 9–12 months after revascularisation, 50 patients with ischaemic cardiomyopathy
(LVEF 32 (8)%) and substantial myocardial viability (> 4 viable segments) underwent radionuclide
ventriculography and dobutamine stress echocardiography. Patients were divided into group 1, patients
with, and group 2, patients without significant improvement in resting LVEF (> 5% by radionuclide
ventriculography) after revascularisation. The response of LVEF during dobutamine stress echocardio-
graphy was compared in these two groups.
Results: Groups 1 and 2 were comparable in baseline characteristics, resting LVEF, and number of viable
segments (mean (SD) 7 (4) v 6 (2), not significant). After revascularisation, the LVEF response during
dobutamine stress echocardiography improved significantly in both groups (group 1, 34 (10)% to 56 (8)%;
group 2, 32 (10)% to 46 (11)%; both p , 0.001). Interestingly, although resting LVEF did not improve in
group 2, peak stress LVEF after revascularisation did (p , 0.001). Group 1 patients had, however, a
greater increase in peak stress LVEF (group 1, 22 (10)%; group 2, 13 (9)%; p , 0.01). New York Heart
Association and Canadian Cardiovascular Society classes decreased in both groups.
Conclusions: Although patients with viable myocardium did not always have improved rest LVEF after
revascularisation, peak stress LVEF improved. Assessment of improvement of resting function may not be
the ideal end point to evaluate successful revascularisation.
A
ssessment of myocardial viability is important in the
management of patients with ischaemic cardiomyo-
pathy. In patients with a substantial amount of viable
myocardium, left ventricular (LV) dysfunction is likely to
improve after coronary revascularisation.1 Improvement of
resting LV ejection fraction (LVEF) has often been used to
assess the success of coronary revascularisation of viable
myocardium.1–8 Previous studies have reported a variable
proportion of patients with viable myocardium with
improved LVEF after revascularisation, ranging from 36–
88%.3 5 Hence, resting LVEF does not always improve after
revascularisation despite the presence of substantial myo-
cardial viability. It has been suggested that contractile reserve
may improve during inotropic stimulation after revascular-
isation even though resting function does not improve.9 10
However, information about peak stress LVEF (as a marker of
cardiac stress performance) after revascularisation is lacking.
In particular, whether patients with viable myocardium who
do not have improved resting LVEF may have improved peak
stress LVEF after revascularisation is unknown. In the
present study, combined low and high dose dobutamine
stress echocardiography (DSE) was performed before and
after revascularisation to evaluate postoperative changes in
stress LVEF in patients with and without improvement in
resting LVEF.
METHODS
Study population
The study population consisted of 56 patients (44 men, mean
(SD) age 60 (11) years) with ischaemic cardiomyopathy
(LVEF 32 (8)%) and a substantial amount of viable
myocardium (> 4 segments, > 25% of the LV) who were
already scheduled for coronary revascularisation. Seven of
these patients had taken part in a previous study.11 All
patients had heart failure symptoms (mean (SD) New York
Heart Association (NYHA) class 3.1 (0.7)), and 70% had
accompanying angina pectoris (Canadian Cardiovascular
Society (CCS) class 2.5 (0.6)). A history of myocardial
infarction was present in 54 patients (96%). In these patients,
myocardial infarction had occurred > 6 months before the
study (median three years, range 0.7–22 years). The decision
for revascularisation was based on clinical grounds (symp-
toms, presence or absence of ischaemia, and angiographic
findings). Patients with severe (grade 3 to 4) mitral
regurgitation were not included. Revascularisation was
performed by coronary artery bypass grafting in 45 patients
(80%) and by angioplasty in 11 patients (20%). None of the
patients had a perioperative myocardial infarction. Two
patients (4%) died during the postoperative period (within
30 days) and four patients (one treated by angioplasty and
three treated by bypass surgery) were excluded because of
incomplete revascularisation according to the procedure
report. Therefore, the final study population consisted of 50
patients (40 men, mean (SD) age 61 (11) years). These
patients had complete revascularisation and were stable
during the study period.
Abbreviations: CCS, Canadian Cardiovascular Society; DSE,
dobutamine stress echocardiography; LV, left ventricular; LVEF, left
ventricular ejection fraction; NYHA, New York Heart Association; RNV,
radionuclide ventriculography
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Study protocol
The study protocol was prospectively designed to evaluate the
response of LVEF to dobutamine challenge before and after
revascularisation. DSE was performed one week before and
9–12 months after revascularisation. Radionuclide ventricu-
lography (RNV) was also performed before and 9–12 months
after revascularisation to assess improvement of resting LVEF
by an independent technique. b Blockers were not discon-
tinued before DSE and RNV. An improvement in LVEF > 5%
after revascularisation was considered clinically significant.5
According to the presence or absence of significant improve-
ment in resting LVEF after revascularisation, the patients
were divided into two groups: group 1, patients with
improved resting LVEF; and group 2, patients without
improved resting LVEF. Next, the response of LVEF during
dobutamine stress before and after revascularisation was
compared in these two groups. In addition, heart failure
symptoms and angina score were evaluated during the study
period. The local ethics committee approved the protocol and
all patients gave informed consent to participate in the study.
Assessment of LVEF
Before and 9–12 months after revascularisation, RNV was
performed to assess LVEF improvement by an independent
technique. RNV was performed at rest with the patient in the
supine position after the administration of 740 MBq of
99mtechnetium. Images were acquired with a small field of
view gamma camera (Orbiter; Siemens Corp, Iselin, New
Jersey, USA) oriented in the 45˚left anterior oblique position
with a 5–10˚caudal tilt. LVEF was calculated from the 45˚left
anterior oblique view by an automated technique. An
improvement in LVEF > 5% after revascularisation was
considered clinically significant.5
Dobutamine stress echocardiography
All echocardiograms were recorded by commercially available
equipment (Sonos 5500; Hewlett Packard, Philips Medical
Systems, Eindhoven, the Netherlands) with a second
harmonic 1.8–3.6 MHz transducer to optimise endocardial
border visualisation. Standard parasternal and apical views of
the LV were obtained12 at rest and at the end of each step of
dobutamine infusion. Dobutamine was administered intra-
venously as previously described,13 starting at a dose of 5 mg/
kg/min for five minutes, followed by 10 mg/kg/min for five
minutes. Subsequently, incremental dobutamine doses of
10 mg/kg/min were given at three minute intervals up to a
maximum dose of 40 mg/kg/min. Atropine (up to 2 mg) was
administered intravenously if the test end point was not
reached. Blood pressure, cardiac rhythm, and ST segment
were continuously monitored.
Test end points were achievement of target heart rate,
extensive new wall motion abnormalities, horizontal or down
sloping ST segment depression (> 2 mm compared with
baseline), severe angina, systolic blood pressure fall
. 40 mm Hg, blood pressure . 240/120 mm Hg, and sig-
nificant supraventricular or ventricular arrhythmia.
Metoprolol (1–5 mg intravenously) was available to reverse
the effects of dobutamine. Severely dysfunctional segments
(including severe hypokinesia, akinesia, and dyskinesia)
were evaluated for the presence of viability. Segments with
a sustained improvement in wall motion up to high dose
dobutamine and segments with a biphasic response or
worsening of wall motion during DSE were considered
viable.5 Segments with unchanged wall motion and segments
with akinesia becoming dyskinesia were considered non-
viable.5 A substantial amount of viable myocardium was
defined as the presence of > 4 viable segments.5 This
definition is based on previous work with receiver operating
characteristic curve analysis showing that recovery of
function may be predicted in the presence of > 4 viable
segments.5
Assessment of response in LVEF to high dose
dobutamine
The study results were analysed off line. LV volumes were
measured at rest and during low and high dose dobutamine
Table 1 Baseline characteristics
Group 1: improvers
(n = 26)
Group 2: non-improvers
(n = 24) p Value
Men 22 (85%) 18 (75%) NS
Age (years) 62 (12) 60 (12) NS
Previous MI 24 (92%) 24 (100%) NS
Q wave MI 20 (83%) 21 (87)% NS
Anterior MI 14 (54%) 15 (62%) NS
NYHA class 3.15 (0.8) 2.96 (0.7) NS
CCS class 2.57 (0.7) 2.67 (0.6) NS
Stenotic vessels 2.4 (0.7) 2.7 (0.6) NS
Smoking 12 (46%) 14 (58%) NS
Hypertension 22 (85%) 21 (87%) NS
Hypercholesterolaemia 16 (61%) 13 (54%) NS
Family history of CAD 13 (50%) 16 (67%) NS
Diabetes mellitus 1 (5%) 2 (8%) NS
Lipid lowering drugs 13 (50%) 10 (42%) NS
ACE inhibitors 17 (65%) 19 (79%) NS
Nitrates 22 (85%) 19 (79%) NS
b Blockers 16 (61%) 16 (67%) NS
Diuretics 12 (46%) 16 (67%) NS
Digoxin 4 (15%) 7 (29%) NS
Aspirin/anticoagulant 26 (100%) 22 (92%) NS
LVEF (%)* 33 (10) 32 (7) NS
LV end diastolic volume (ml) 160 (59) 194 (39) ,0.05
LV end systolic volume (ml) 105 (49) 135 (37) ,0.05
LV sphericity index 0.58 (0.09) 0.61 (0.11) NS
Data are mean (SD) or number (%).
*Assessed by radionuclide ventriculography.
Derived by the ratio of left ventricular (LV) short to long axis dimensions in the apical four chamber view.15
ACE, angiotensin converting enzyme; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society;
LVEF, left ventricular ejection fraction; MI, myocardial infarction; NS, not significant; NYHA, New York Heart
Association.
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infusion with the biplane disk method, a modification of
Simpson’s rule.12 Subsequently, the LVEF at baseline and
during low and high dose dobutamine were calculated by
using the following equation: [end diastolic volume 2 end
systolic volume]/end diastolic volume. All measurements
were taken by an independent, experienced reader blinded to
the clinical data and time of the study. Interobserver and
intraobserver variability for LVEF calculation were reported
previously (3.3% and 5.3% respectively).14
Assessment of functional status
Before and after revascularisation, an independent physician
blinded to all data conducted structured clinical interviews to
assess the functional status according to the NYHA (for
symptoms of heart failure) and the CCS (for angina) criteria.
Statistical analysis
Continuous data are expressed as mean (SD) and dichot-
omous data as proportions. Continuous data were compared
by Student’s t test for paired and unpaired samples and two
way analysis of variance to evaluate differences across time
and between different groups, as indicated. Proportions was
compared by x2 analysis. For all tests, p , 0.05 was
considered significant.
RESULTS
Improvement of resting LVEF after revascularisation
After revascularisation, resting LVEF improved significantly
(> 5%) in 26 patients (group 1) whereas it failed to improve
in 24 patients (group 2). In particular, resting LVEF increased
on average from 33 (10)% to 43 (10)% (p , 0.001) in group
1, whereas a slight but significant decrease was observed in
group 2 (from 32 (7)% to 30 (7)%, p , 0.05). Baseline clinical
characteristics of patients with (group 1) and without (group
2) improved resting LVEF were comparable (table 1).15
Resting LVEF by RNV and LV sphericity index were similar
in the two groups (table 1), whereas LV end diastolic and end
systolic volumes were significantly larger in group 2 (table 1).
In addition, group 1 and group 2 were comparable in the
extent of viable myocardium (7.4 (4) and 6.0 (2) segments,
not significant) but group 2 patients had a larger extent of
scar tissue (6.1 (2.3) v 3.7 (3.0), p , 0.05).
DSE before and after revascularisation
The haemodynamic response during DSE was similar before
and after revascularisation in the two groups. In particular,
the peak rate–pressure product was 16.270 (2.895) v 16.057
(2.902) (not significant) in group 1 and 16.897 (3.226) v
16.208 (3.225) (not significant) in group 2. The proportion of
patients who reached 85% of the age predicted target heart
rate was also similar before and after revascularisation (98% v
92%, respectively, not significant). Before and after revascu-
larisation, medication (including b blockers) was compar-
able; only the use of nitrates was significantly reduced
postoperatively (85% v 19%, p , 0.001, in group 1 and 79% v
25%, p , 0.001, in group 2). Table 2 shows the patterns of
LVEF response during low and high dose DSE. Before
revascularisation, LVEF had increased during low dose
dobutamine infusion and deteriorated at peak DSE in both
group 1 and group 2 (p , 0.001 by analysis of variance). The
magnitude of change in LVEF during DSE was slightly higher
in group 1 than in group 2 (p = 0.03 by analysis of
variance). After revascularisation, LVEF increased during
low dose dobutamine infusion and remained increased at
peak DSE in the two groups (both p , 0.001 by analysis of
variance). The improvement in LVEF response during DSE
after revascularisation was significant in both groups
(p , 0.001 by analysis of variance) (table 2). In group 1
peak stress LVEF after revascularisation improved signifi-
cantly compared with peak stress LVEF before revascularisa-
tion (p , 0.001) (fig 1). Interestingly, after revascularisation,
although resting LVEF had not improved in group 2, peak
stress LVEF did also improve significantly in these patients
(p , 0.001) (fig 1). In particular, 19 of 24 patients (79%)
without improved resting LVEF had improved peak stress
LVEF. The magnitude of improvement in LVEF at high dose
dobutamine was higher in group 1 than in group 2 (22 (10)%
v 13 (9)%, p , 0.01).
Functional status
After revascularisation all patients had a significant improve-
ment in heart failure and angina symptoms (fig 2). In
particular, the mean (SD) NYHA functional class improved
from 3.2 (0.8) to 1.8 (0.7) in group 1 (p , 0.001) and from
3.0 (0.7) to 2.2 (0.8) in group 2 (p , 0.01). Similarly, the CCS
class improved from 2.6 (0.7) to 1.3 (0.7) in group 1 and from
2.7 (0.6) to 1.3 (0.6) in group 2 (both p , 0.001).
Table 2 LVEF (%) during dobutamine stress echocardiography
Before revascularisation* After revascularisation**
p ValueRest LD Peak p Value Rest LD Peak p Value
Group
1 34 (8) 46 (11) 34 (10) ,0.001 43 (9) 54 (8) 56 (8) ,0.001 ,0.001
Group
2 31 (8) 41 (9) 32 (10) ,0.001 31(7) 44 (10) 46 (11) ,0.001 ,0.001
*p= 0.03 group 1 v group 2; ** p,0.001 group 1 v group 2; p value before versus after revascularisation for the
pattern of response during dobutamine stress echocardiography.
LD, low dose.
60
40
50
30
20
0
10
Before
Pe
ak
 s
tre
ss
 LV
EF
 (%
)
Group 1 Group 2
p < 0.001 p < 0.001
After
Figure 1 Bar graph showing the effect of revascularisation on peak
stress left ventricular ejection fraction (LVEF) in viable patients with
(group 1) and without (group 2) improvement of resting LVEF. After
revascularisation, peak stress LVEF improved even in viable patients
without improvement in resting LVEF.
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DISCUSSION
Improvement of LVEF after coronary revascularisation has
been described in variable proportions of patients with
ischaemic cardiomyopathy and substantial myocardial viabi-
lity. The findings in the present study showed that, although
resting LVEF did not improve in 48% of patients with
substantial viability, peak stress LVEF did improve compared
with before revascularisation.
Beneficial effect of coronary revascularisation on
resting LV function
Postoperative improvement of LV function has been con-
sidered the bench mark against which the preoperative
methods to assess viability are measured.8 Initial studies
showed that regional LV function improved after revascular-
isation, whereas in more recent studies global LV function
improved.8 It has become clear that substantial myocardial
viability is needed to obtain functional improvement.4–7 16 Bax
and colleagues5 showed that LVEF improved in 82% of
patients with substantial viable myocardium. However, other
studies have shown that resting LVEF does not always
improve after revascularisation.3 4 6–10 14 16 In the present
study, only patients with a substantial amount of viable
myocardium (at least 25% of the LV) were included. After
revascularisation, however, only 52% of the patients had
significantly improved resting LVEF. Similarly, in the study
by Pasquet and colleagues7 resting LVEF after revascularisa-
tion improved significantly in only 47% of patients shown by
low and high dose DSE and nuclear imaging to have
extensive viability.7 These varying percentages of patients
experiencing recovery in LVEF after revascularisation are
likely to be related to different characteristics of study
populations. In particular, besides myocardial viability,
additional factors may play a part in determining functional
recovery after coronary revascularisation. It has been shown
that the presence of extensive scar tissue may prohibit the
increase of LVEF after revascularisation, despite viable
myocardium.11 17 Accordingly, in the present study the extent
of scar tissue was larger in the patients who did not have
improved LVEF. Also advanced LV remodelling may limit the
improvement in LVEF despite the presence of viable
myocardium.2 18–20 In the present study, baseline LV end
diastolic and end systolic volumes were significantly larger in
patients who did not have improved LVEF after revascular-
isation. Finally, delayed revascularisation and graft occlusion
or restenosis after intervention may prevent functional
recovery of viable myocardium.21 22
Effect of coronary revascularisation on LVEF response
to dobutamine challenge
In the present study, resting LVEF improved in only 52% of
patients, despite the presence of substantial viability. It has
been suggested that, although resting function does not
improve, the contractile reserve may increase during ino-
tropic challenge after revascularisation.9 10 In the study by
Lombardo and colleagues,9 resting function did not improve
after revascularisation in 57% of the dysfunctional regions
shown by DSE to be viable before revascularisation. However,
the contractile reserve was observed to increase during low
dose dobutamine infusion in these regions after revascular-
isation. Elhendy and colleagues10 showed that LVEF during
low dose dobutamine challenge increased even in patients
who did not have improved resting LVEF after revascularisa-
tion. The responses of LVEF to high dose dobutamine after
revascularisation (representing cardiac stress performance)
have not been reported thus far.
In the present study, we evaluated the response of LVEF to
combined low and high doses of dobutamine infusion in
patients with (group 1) and without (group 2) improved
resting LVEF after revascularisation. Before revascularisation,
LVEF improved at low dose followed by a deterioration at
high dose dobutamine (biphasic response). After revascular-
isation, although resting LVEF did not improve in 48% of
patients with viable myocardium, peak stress LVEF did
improve. Therefore, postoperative DSE identified additional
patients who benefited from revascularisation in terms of
global stress function, even though resting function did not
improve. Although previous studies have shown that addi-
tional benefits (besides recovery of resting function) may be
present after revascularisation, the present study uniquely
showed that peak LVEF improved in patients without
improved resting LVEF.
In a previous study that used a comparable low and high
dose DSE protocol, Afridi and colleagues23 showed that the
wall motion score index at peak stress also improved in
patients without improved resting function (defined as an
improvement of the wall motion score by > 2 grades in at
least two contiguous segments). The findings in the present
study are in line with this observation and show the
beneficial effect of revascularisation on cardiac stress
performance. Relief of ischaemia by restoration of the
coronary flow reserve may be the mechanism responsible
for maintaining the contractile function up to peak stress.
This hypothesis is supported by data from Elhendy and
colleagues10 showing that the ischaemic score according to
thallium-201 imaging decreased significantly after revascu-
larisation in both patients with and patients without
improved resting LVEF. Also, in the study by Afridi and
colleagues,23 the majority of the improvement in stress wall
motion score occurred in patients with evidence of ischaemia
before revascularisation.
In line with previous studies, the observations in the
present study suggest that assessment of resting LVEF after
revascularisation may not be the ideal end point to evaluate
the success of coronary revascularisation. Assessment of
LVEF response to low and high dose DSE after revascularisa-
tion may be a more appropriate strategy to evaluate fully the
benefit of revascularisation. The improvement of LVEF up to
high dose dobutamine suggests the presence of a sustained
contractile reserve and the absence of significant ischaemia.
Preservation of contractile reserve and relief of ischaemia
may be important in improving the prognosis of patients with
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Figure 2 Bar graph showing the effect of revascularisation on heart
failure and angina symptoms. After revascularisation, New York Heart
Association (NYHA) and Canadian Cardiovascular Society (CCS)
classes improved significantly both in patients with (group 1) and in
patients without (group 2) improvement in resting LVEF.
322 Rizzello, Poldermans, Biagini, et al
www.heartjnl.com
 on 25 October 2006 heart.bmjjournals.comDownloaded from 
ischaemic cardiomyopathy by preventing LV remodelling and
ischaemia related arrhythmias.24
Implications of improved stress function
Post-revascularisation improvement of heart failure symp-
toms has been shown to relate to the presence of viable
myocardium before revascularisation.5 9 25 26 This was also
observed in the current study. It is conceivable that improved
stress LVEF may relate to improved functional class. It has
been also shown that patients with myocardial viability who
underwent revascularisation had a better prognosis than did
medically treated patients.27 28 This superior prognosis may
also (in part) be related to the improvement of stress LVEF
(reflecting absence of ischaemia). Further studies are needed
to clarify this issue.
Limitations
Coronary angiography was not repeated after revascularisa-
tion, nor was perfusion imaging performed. Therefore, failure
of resting LVEF to improve because of graft closure or
restenosis after intervention cannot be excluded. However,
none of the patients had an ischaemic response to DSE after
revascularisation. The study population is relatively small.
Further studies with more patients are needed to clarify the
prognostic implications of these findings.
Conclusion
Assessment of resting LV function has been used as the yard
stick to evaluate the success of coronary revascularisation in
patients with ischaemic cardiomyopathy and viable myocar-
dium. The findings in the present study showed that
assessment of resting LVEF may underestimate the benefit
of revascularisation, since stress LVEF may improve even in
patients without improved resting LVEF. Moreover, the
improvement in stress LVEF was accompanied by improved
functional status.
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